[제약&바이오] Samjin Pharmaceutical
Samjin Pharmaceutical (CEO Choi Yong-joo) has launched ‘Elsaban Tablets 2.5㎎·5㎎’, an oral anticoagulant (NOAC), which is a blood coagulation factor (Factor Ⅹa) inhibitor, as a finished medicine produced by the company. Elsaban Tablet is a Xaban-based medication that reduces the risk of stroke and systemic embolism by suppressing the formation of blood clots caused by slowed blood flow in patients with atrial fibrillation.
According to Real World data, it has been confirmed that Apixaban, the ingredient in Elsaban tablets, has equal or better efficacy than warfarin, a conventional anticoagulant, and has a low risk of bleeding. In addition, its effectiveness and safety have already been proven, with a pharmacokinetic lower relative renal excretion rate than other NOAC preparations, making it less burdensome for patients with impaired renal function.
In particular, research results have been published showing that the risk of bleeding was lower when apixaban and clopidogrel were administered in combination with apixaban in the treatment of atrial fibrillation patients with acute coronary syndrome (ACS) or who underwent percutaneous coronary intervention (PCI) compared to the warfarin group. there is. Accordingly, a synergistic effect between Elsavan Tablet and the anti-platelet aggregation inhibitor ‘Pleris Tablet’ is also expected.
The prevalence of atrial fibrillation is predicted to reach approximately 5.8% of the domestic population by 2060, and the rate of anticoagulant treatment for patients with atrial fibrillation is also trending higher. In atrial fibrillation, complications such as stroke and systemic embolism caused by blood clots are more fatal than the symptoms themselves, so appropriate anticoagulation therapy must be administered depending on the risk.
A Samjin Pharmaceutical official said, “Elsaban Tablet will lead to groundbreaking sales growth in the circulatory medicine market through synergy with the existing antithrombotic drug lineup, Flaris Tablet and ‘Rivoxaban Tablet’. “We will do our best to establish ourselves as a leading product.”
Reporter Park Ji-hye [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-09-30 02:49:24